BACKGROUND AND OBJECTIVE: The immune function disorder relates closely to the occurrence, @entity3 , and prognosis of @entity5 . T lymphocyte subsets take an important role in immune function. We identified the dynamic changes of the immune system by investigating the levels of T lymphocyte subsets in peripheral blood of @entity2 @entity1 with advanced stage @entity420 undergoing first line chemotherapy. The results aided the search for rational chemo-immunotherapy strategies in @entity2 treatment. METHODS: Samples from 49 @entity1 with pathologically demonstrated advanced stage @entity2 were compared with those from 33 healthy donors. Subsequently, the @entity1 were separately treated with @entity1205 -based or Pemetrexed-based therapy. Peripheral blood samples at different time points after therapy were analyzed by flowcytometry. The lymphocyte subsets of the total lymphocytes were compared. Independent sample t test was used for the quantitative data analysis. RESULTS: The percentage of CD3+, CD3+ @entity404 +, @entity404 +CD25+ cells of the @entity2 @entity1 significantly varied from those of the healthy donors, the P values are 0.012, 0.034 and 0.006 separately. The CD3+ and CD3+ @entity404 + levels increased significantly on the 4th and 7th-10th day post-chemotherapy, which return to normal levels on the 21th day. The CD3+ level increased significantly both in the treatment group on all time points, while the CD3+, CD3+ @entity404 +, @entity404 +/ @entity405 + levels significantly increased and the CD3+ @entity405 +, @entity405 +CD28- levels significantly decreased on the 4th day in Pemetrexed group. The CD3+ @entity404 + levels increased significantly on the 4th and 7th-10th day and the CD3+ @entity405 +, @entity405 +CD28- levels decreased on the 4th day in partial response group. CONCLUSIONS: The immune function of advanced stage @entity2 @entity1 was evidently suppressed, and was restored at the 4th day, followed by a reduction at the 21st day after chemotherapy. On the 4th day, Pemetrexed showed better effect on the immune system. The change of immune system post-chemotherapy could be related with the prognosis.

[Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from @entity1 with advanced stage XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity404 :: ('920', 'Gene') :: ['CD4'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer', 'adenocarcinoma cell lung cancer'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['Docetaxol'] @entity405 :: ('925', 'Gene') :: ['CD8'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity2 :: (MESH:D008175,Disease) :: ['adenocarcinoma cell lung cancer']
